Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.

Abstract: A system to generate image representations includes a first objective that receives a first light beam emitted from a sample and a second objective that receives a second light beam emitted from the sample, where the first light beam and the second light beam have conjugate phase. The system also includes a first diffractive element to receive the first light beam and separate it into a first plurality of diffractive light beams that are spatially distinct, and a second diffractive element to receive the second light beam and separate it into a second plurality of diffractive light beams that are spatially distinct. The system further includes a detector that receives the first and second plurality of diffractive light beams. The first plurality of diffractive light beams and the second plurality of diffractive light beams are simultaneously directed and focused onto different portions of an image plane of the detector.

Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Abstract: Embodiments are directed to therapeutic, diagnostic, or functional complexes comprising a kethoxal derivative.

Abstract: The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.

Abstract: A method of facilitating bidirectional programming of a user may include receiving an original program source code and evaluating the original program source code in the forward direction to generate a program output. The evaluation may occur in a programming environment. The program output may be displayed, and an indication of the user corresponding to modifying the program output may be received. The modified program output may be evaluated to generate an updated program source code, wherein the updated program source code, when evaluated, may generate the modified program output. The modified program output may be displayed in a display device of the user. A computing system including a bidirectional programming environment may also be included.

Abstract: Provided are a superlattice structure including a two-dimensional material and a device including the superlattice structure. The superlattice structure may include at least two different two-dimensional (2D) materials bonded to each other in a lateral direction, and an interfacial region of the at least two 2D materials may be strained. The superlattice structure may have a bandgap adjusted by the interfacial region that is strained. The at least two 2D materials may include first and second 2D materials. The first 2D material may have a first bandgap in an intrinsic state thereof. The second 2D material may have a second bandgap in an intrinsic state thereof. An interfacial region of the first and second 2D materials and an adjacent region may have a third bandgap between the first bandgap and the second bandgap.

Abstract: A multi-spectral tomography imaging system includes one or more source devices configured to direct beams of radiation in multiple spectra to a region of interest (ROI), and one or more detectors configured to receive the beams of radiation. The system includes a processor configured to cause movement in at least one of the components such that a first beam of radiation with a first spectrum is directed to the ROI for less than 360 degrees of movement of the ROI. The processor is also configured to process data detected by the one or more detectors, where the data results at least in part from the first beam of radiation with the first spectrum that is directed to the ROI for less than the 360 degrees of movement of the ROI. The processor is further configured to generate an image of the ROI based on the processed data.

Abstract: The present invention provides microfabricated substrates and methods of conducting reactions within these substrates. The reactions occur in plugs transported in the flow of a carrier-fluid.

Abstract: In an emission imaging method, emission imaging data are acquired for a subject using an emission imaging scanner (10) including radiation detectors (12). The emission imaging data are reconstructed to generate a reconstructed image by executing a constrained optimization program including a measure of data fidelity between the acquired emission imaging data an a reconstruct-image transformed by a data model of the imaging scanner to emission imaging data. During the reconstructing, each iteration of the constrained optimization program is constrained by an image variability constraint. The reconstructed image is displayed the reconstructed image on a display device. The emission imaging may be positron emission tomography (PET) imaging data, optionally acquired using a sparse detector array. The image variability constraint may be a constraint that an image total variation (image TV) of a latent image defined using a Gaussian blurring matrix be less than a maximum value.

Abstract: A computing device may receive a first set of training data for training an ANN to predict output data for a first task, and may train the ANN with the first set of training data by only adjusting values of weights associated with a first subset of neurons, the first subset selected based on an identity of the first task. The computing device may receive a second, different set of training data for training the ANN to predict output data for a second task, and may train the ANN with the second set of training data by only adjusting values of weights associated with a second subset of neurons, the second subset selected based on an identity of the second task. During training, adjusting of the value of any weight may entail weight stabilization that depends on whether there has been any training for one or more previous tasks.

Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Abstract: Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.

Abstract: Aspects of the disclosure relate to a RNA regulatory system comprising at least one of each: i) a RNA hairpin binding domain; ii) a RNA targeting molecule comprising a RNA targeting region and at least one hairpin structure, wherein the hairpin structure of the RNA targeting molecule specifically binds to i; and iii) a RNA regulatory domain.

Abstract: The disclosure provides Tn epitope-specific chimeric antigen receptors and scFvs, including soluble scFvs and multimeric scFvs, as well as methods of identifying cancer subjects and cancer subject sub-populations amenable to anti-Tn immunotherapy and methods of treating cancer.

Abstract: The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.

Abstract: Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.

Abstract: A controller is provided to determine a ventricular filling phase slope as an indicator of high pulmonary capillary wedge pressure and/or cardiac index. Flow rate values describing a blood flow rate through a ventricular assist device are received. A ventricular filling phase segment is identified from a portion of the received flow rate values. A slope of the received flow rate values during the identified ventricular filling phase segment is determined. The determined slope is compared to a predetermined threshold value. When the determined slope exceeds the predetermined threshold value based on the comparison, a warning is triggered regarding an elevated pulmonary capillary wedge pressure or a low cardiac index value.

Abstract: Methods of synthesizing colloidal ternary Group III-V nanocrystals are provided. Also provided are the colloidal ternary Group III-V nanocrystals made using the methods. In the methods, molten inorganic salts are used as high temperature solvents to carry out cation exchange reactions that convert binary nanocrystals into ternary nanocrystals.

Abstract: Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.